

This article was downloaded by:

On: 26 January 2011

Access details: *Access Details: Free Access*

Publisher *Taylor & Francis*

Informa Ltd Registered in England and Wales Registered Number: 1072954 Registered office: Mortimer House, 37-41 Mortimer Street, London W1T 3JH, UK



Nucleosides, Nucleotides and Nucleic Acids

Publication details, including instructions for authors and subscription information:

<http://www.informaworld.com/smpp/title~content=t713597286>

Synthesis of a Nucleoside Bioconjugate System as a Potential Anti-HIV Agent

Serge Van Calenbergh^a; Vasu Nair^a

^a Department of Chemistry, The University of Iowa, Iowa City, Iowa, U.S.A.

To cite this Article Van Calenbergh, Serge and Nair, Vasu(1999) 'Synthesis of a Nucleoside Bioconjugate System as a Potential Anti-HIV Agent', *Nucleosides, Nucleotides and Nucleic Acids*, 18: 4, 737 — 738

To link to this Article: DOI: 10.1080/15257779908041559

URL: <http://dx.doi.org/10.1080/15257779908041559>

PLEASE SCROLL DOWN FOR ARTICLE

Full terms and conditions of use: <http://www.informaworld.com/terms-and-conditions-of-access.pdf>

This article may be used for research, teaching and private study purposes. Any substantial or systematic reproduction, re-distribution, re-selling, loan or sub-licensing, systematic supply or distribution in any form to anyone is expressly forbidden.

The publisher does not give any warranty express or implied or make any representation that the contents will be complete or accurate or up to date. The accuracy of any instructions, formulae and drug doses should be independently verified with primary sources. The publisher shall not be liable for any loss, actions, claims, proceedings, demand or costs or damages whatsoever or howsoever caused arising directly or indirectly in connection with or arising out of the use of this material.

SYNTHESIS OF A NUCLEOSIDE BIOCONJUGATE SYSTEM AS A POTENTIAL ANTI-HIV AGENT

Serge Van Calenbergh and Vasu Nair *


Department of Chemistry, The University of Iowa, Iowa City, Iowa 52242, U.S.A.

ABSTRACT: Synthesis and anti-HIV data for a bioconjugate molecule incorporating a HIV protease inhibitor (A74704) and a HIV RT inhibitor (d4T) are presented.

Current antiviral therapy for the human immunodeficiency virus (HIV) is based largely on the inhibition of two viral enzymes that play essential roles in the replication of HIV, i.e., HIV reverse transcriptase (HIV RT) and HIV protease (HIV PR).¹ More recent approaches to therapy have involved combinations of antiviral agents.² These findings led us to the synthesis and *in vitro* anti-HIV evaluation of a bioconjugate molecule **3** consisting of a HIV RT inhibitor and a HIV protease inhibitor.

Compound **3** was constructed by combining the known disubstituted methanol analog **1** (Abbot, A74704) as the HIV PR inhibitor,³ and d4T [1-(2,3-dideoxy- β -D-glycero-pent-2-enofuranosyl)thymine] as the HIV RT inhibitor.⁴ Compound **1** was obtained following a described multi-step procedure.⁵ d4T was synthesized as previously reported.⁶ As a first linker, succinic acid was selected. Esterification of **1** with succinic anhydride/ DMAP in CH_2Cl_2 provided, after work-up, a 64% yield of the ester **2**. Reaction of the carboxyl functionality of **2** with the 5'- CH_2OH group of d4T (DCC, catalytic DMAP) afforded the desired succinyl diester **3** in 40% yield. The structure and stereochemistry of the target compound was established by FAB mass spectral data and extensive NMR studies. Assignment of the signals in the ^1H NMR spectra of compound **1** and the target bioconjugate molecule **3** was aided by COSY and HMQC experiments.

One criterion that a successful bioconjugate molecule must satisfy is that of its cellular conversion to the pharmacologically active species. However, compound **3** exhibited resistance to hydrolysis with porcine lipase, while only marginal hydrolysis (< 20%) was achieved rabbit liver esterase. Consistent with this was the inactivity of **3** against HIV-1 (IIIB) and HIV-2 (ROD) at subtoxic concentrations in acutely infected MT-4 cells or in chronically infected HUT-78 IIIB cells.



Acknowledgments. We thank Professor Erik De Clercq for the anti-HIV data. This research work was supported by the National Institutes of Health (NIAID).

REFERENCES

1. De Clercq, E. *Clin. Microb. Rev.* **1995**, *8*, 200-239.
2. Carpenter, C.C.J.; Fischl, M.A.; Hammer, S.M.; Hirsch, M.S.; Jacobsen, D.M.; Katzenstein, D.A.; Montaner, J.; Richman, D. D.; Saag, M.S.; Schooley, R.T.; Thompson, M.; Vella, S.; Yeni, P.; Volberding, P. *JAMA* **1997**, *277*, 1962-1969.
3. Erickson, J.; Neidhart, D.J.; VanDrie, J.; Kempf, D.J.; Wang, X.C.; Norbeck, D.W.; Plattner, J.J.; Rittenhouse, J.W.; Turon, M.; Wideburg, N.; Kohlbrenner, W.E.; Simmer, R.; Helfrich, R.; Paul, D.A.; Knigge, M. *Science* **1990**, *249*, 527-533.
4. Baba, M.; Pauwels, R.; Herdewijn, P.; De Clercq, E.; Desmyter, J.; Vandeputte, M. *Biochem. Biophys. Res. Commun.* **1987**, *142*, 128-134. Lin, T. S.; Schinazi, R. F.; Prusoff, W. H. *Biochem. Pharmacol.* **1987**, *36*, 2713-2718.
5. Kempf, D.J.; Codacovi, L.M.; Wang, X. C.; Kohlbrenner, W.E.; Wideburg, N.E.; Saldivar, A.; Vasavanonda, S.; Marsh, K.C.; Bryant, P.; Sham, H.L.; Green, B.E.; Betebenner, D.A.; Erickson, J.; Norbeck, D.W. *J. Med. Chem.* **1993**, *36*, 320-330.
6. Horwitz, J. P.; Chua, J. In *Synthetic Procedures in Nucleic Acid Chemistry*, Interscience: New York, 1968, Vol. 1, pp 344-346.